Get the Stockscreener App
1.61
0.63%
0.01
After Hours:
1.58
-0.03
-1.86%
Metagenomi Therapeutics Inc Stock (MGX) Forecast
The Metagenomi Therapeutics Inc (MGX) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $26.24, representing a +1,530% increase from the current price of $1.61. The highest analyst price target is $27.70, and the lowest is $24.78.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month MGX Price Target
Average 31.04
(+1,828% Upside)
Is Metagenomi Therapeutics Inc (MGX) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 55.10 | Neutral |
| STOCH(9,6) | 68.98 | Neutral |
| STOCHRSI(14) | 100.00 | Sell |
| MACD(12,26) | -0.00809 | Buy |
| ADX(14) | 14.56 | Neutral |
| William %R | -29.82 | Neutral |
| CCI(14) | 156.16 | Buy |
Buy: 2
Sell: 1
Neutral: 4
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
1.529
Buy
|
1.5457
Buy
|
| MA20 |
1.511
Buy
|
1.5405
Buy
|
| MA50 |
1.6044
Buy
|
1.616
Sell
|
| MA100 |
1.8751
Sell
|
1.7492
Sell
|
| MA200 |
1.9155
Sell
|
1.9061
Sell
|
Buy: 5
Sell: 5
Neutral: 0
Summary: Neutral
According to our latest analysis, MGX could be considered a Potential Buy, with 17 technical analysis indicators signaling 7 Buy signals, 6 signaling Sell signals and 4 Neutral signals. This might be a good time to open fresh positions on MGX, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 55.1 indicates that MGX is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 68.98 indicates that MGX is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 100 indicates that MGX is oversold. This suggests that MGX price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 14.56 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 156.16 indicates that MGX is overbought. This means that the price has moved significantly higher than its average, indicating a potential selling opportunity.
Long-term MGX price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Metagenomi Therapeutics Inc financial reports and earnings history, Metagenomi Therapeutics Inc (MGX) stock could reach $97.76 by 2030, $246.35 by 2040 and $350.17 by 2050. See the projected annual prices until 2050 of the Metagenomi Therapeutics Inc stock below:
- Metagenomi Therapeutics Inc (MGX) is expected to reach an average price of $199.36 in 2035, with a high prediction of $198.82 and a low estimate of $118.34. This indicates an $12,283% rise from the last recorded price of $1.61.
- Metagenomi Therapeutics Inc (MGX) stock is projected to chart a bullish course in 2040, with an average price target of $221.03, representing an $13,629% surge from its current level. The forecast ranges from a conservative $221.04 to a sky-high $246.35.
- Our analysts predict Metagenomi Therapeutics Inc (MGX) to jump 21,888% by 2045, soaring from $354.24 to an average price of $354.00, potentially reaching $389.74. While $354.24 is the low estimate, the potential upside is significant.
- Metagenomi Therapeutics Inc (MGX) stock is expected to climb by 2050, reaching an average of $308.76, a $19,077% jump from its current level. However, a wide range of estimates exists, with high and low targets of $350.17 and $308.80, respectively, highlighting the market's uncertainty.
Metagenomi Therapeutics Inc Stock (MGX) Year by Year Forecast
Metagenomi Therapeutics Inc Stock (MGX) Price Forecast for 2026
The predicted value for Metagenomi Therapeutics Inc (MGX) in 2026 is set at an average of $26.90. Estimates vary from a peak of $38.86 to a trough of $14.93, indicating an +1,571% surge from the present price of $1.61.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| April, 2026 | $24.90 | $24.78 | $27.70 | +1,447% |
| May, 2026 | $21.10 | $21.37 | $22.13 | +1,210% |
| June, 2026 | $18.97 | $18.07 | $19.88 | +1,078% |
| July, 2026 | $29.05 | $29.32 | $33.70 | +1,704% |
| August, 2026 | $25.39 | $25.40 | $27.33 | +1,477% |
| September, 2026 | $22.31 | $21.20 | $23.41 | +1,285% |
| October, 2026 | $34.92 | $35.16 | $38.86 | +2,069% |
| November, 2026 | $30.14 | $30.21 | $32.86 | +1,772% |
| December, 2026 | $25.87 | $25.91 | $28.19 | +1,507% |
Metagenomi Therapeutics Inc Stock (MGX) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Metagenomi Therapeutics Inc (MGX) is $41.92, with a high forecast of $59.50 and a low forecast of $24.33. This indicates an +2,504% increase from the last price of $1.61.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $41.47 | $24.33 | $44.02 | +2,476% |
| February, 2027 | $35.06 | $36.45 | $39.49 | +2,078% |
| March, 2027 | $30.37 | $31.40 | $32.90 | +1,786% |
| April, 2027 | $48.15 | $27.47 | $49.18 | +2,891% |
| May, 2027 | $42.43 | $42.70 | $46.08 | +2,535% |
| June, 2027 | $36.32 | $36.39 | $39.03 | +2,156% |
| July, 2027 | $54.88 | $30.60 | $54.34 | +3,309% |
| August, 2027 | $47.19 | $47.46 | $52.72 | +2,831% |
| September, 2027 | $39.88 | $40.15 | $44.85 | +2,377% |
| October, 2027 | $35.77 | $33.73 | $37.81 | +2,122% |
| November, 2027 | $53.69 | $53.93 | $59.50 | +3,235% |
| December, 2027 | $44.95 | $44.96 | $51.01 | +2,692% |
Metagenomi Therapeutics Inc Stock (MGX) Price Forecast for 2028
In 2028, Metagenomi Therapeutics Inc (MGX) is projected to reach an average price of $58.50, with a high projection of $80.14 and a low estimate of $36.87. This indicates an +3,534% rise from the last price of $1.61.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $39.03 | $39.07 | $42.10 | +2,324% |
| February, 2028 | $60.86 | $36.87 | $64.66 | +3,680% |
| March, 2028 | $50.48 | $50.55 | $58.26 | +3,036% |
| April, 2028 | $44.15 | $45.18 | $47.76 | +2,642% |
| May, 2028 | $65.71 | $40.00 | $69.82 | +3,981% |
| June, 2028 | $56.18 | $57.57 | $62.95 | +3,390% |
| July, 2028 | $50.73 | $51.12 | $53.24 | +3,051% |
| August, 2028 | $73.17 | $43.14 | $74.98 | +4,445% |
| September, 2028 | $64.33 | $64.60 | $70.32 | +3,896% |
| October, 2028 | $54.91 | $55.18 | $60.15 | +3,311% |
| November, 2028 | $80.68 | $46.27 | $80.14 | +4,911% |
| December, 2028 | $69.88 | $70.15 | $77.74 | +4,240% |
Metagenomi Therapeutics Inc Stock (MGX) Price Forecast for 2029
The 2029 price forecast for Metagenomi Therapeutics Inc Stock (MGX) is $75.09 on average, with a high prediction of $100.78 and a low estimate of $49.40. This represents an +4,564% increase from the previous price of $1.61.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $58.67 | $58.94 | $66.75 | +3,544% |
| February, 2029 | $52.61 | $49.40 | $55.82 | +3,168% |
| March, 2029 | $77.15 | $77.39 | $85.30 | +4,692% |
| April, 2029 | $66.76 | $66.83 | $73.69 | +4,046% |
| May, 2029 | $55.48 | $55.52 | $63.41 | +3,346% |
| June, 2029 | $85.10 | $52.54 | $90.46 | +5,186% |
| July, 2029 | $73.08 | $74.47 | $81.72 | +4,439% |
| August, 2029 | $61.37 | $62.40 | $69.52 | +3,712% |
| September, 2029 | $93.19 | $55.67 | $95.62 | +5,688% |
| October, 2029 | $77.31 | $78.70 | $89.71 | +4,702% |
| November, 2029 | $68.73 | $69.12 | $73.58 | +4,169% |
| December, 2029 | $101.32 | $58.80 | $100.78 | +6,193% |
Metagenomi Therapeutics Inc Stock (MGX) Price Forecast for 2030
Metagenomi Therapeutics Inc Stock (MGX) is expected to reach an average price of $89.10 in 2030, with a high forecast of $116.26 and a low forecast of $61.94. This signifies an +5,434% surge from the last price of $1.61.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $86.23 | $86.50 | $97.76 | +5,256% |
| February, 2030 | $73.69 | $73.96 | $81.27 | +4,477% |
| March, 2030 | $66.08 | $61.94 | $70.22 | +4,004% |
| April, 2030 | $95.92 | $96.16 | $105.94 | +5,858% |
| May, 2030 | $80.17 | $80.18 | $91.84 | +4,879% |
| June, 2030 | $68.64 | $68.68 | $75.91 | +4,163% |
| July, 2030 | $100.62 | $65.07 | $111.10 | +6,149% |
| August, 2030 | $87.10 | $87.17 | $96.37 | +5,310% |
| September, 2030 | $75.16 | $76.19 | $82.97 | +4,568% |
| October, 2030 | $109.35 | $68.20 | $116.26 | +6,692% |
| November, 2030 | $94.21 | $95.60 | $105.18 | +5,751% |
| December, 2030 | $83.14 | $83.53 | $89.86 | +5,064% |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):